Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719887 | 0.97 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL1271337 | 0.92 | FDPS (0.52) | FDPSSMPD1GGPS1 | |
| SCHEMBL999922 | 0.92 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL5391830 | 0.92 | FDPS (0.52) | FDPSSMPD1GGPS1 | |
| SCHEMBL4368580 | 0.92 | FDPS (0.44) | FDPSSMPD1GGPS1 | |
| SCHEMBL14840328 | 0.86 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL14840392 | 0.86 | — | — | |
| SCHEMBL3032913 | 0.85 | SMN1; SMN2 (0.43) | FDPSSMPD1GGPS1 | |
| SCHEMBL6610045 | 0.85 | FDPS (0.48) | FDPSSMPD1GGPS1 | |
| SCHEMBL4631586 | 0.85 | SMN1; SMN2 (0.57) | FDPSSMPD1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003034989-A3 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARM INC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | DNPEP, ASPH, CTSC | FDPS 1086/4885SMPD1 214/4885GGPS1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.